PerkinElmer unveils cell analysis for gene therapy research

30-Sep-2022

The Cellaca PLX Image Cytometer “redefines workflows” and addresses multiple critical quality attributes

PerkinElmer unveils cell analysis for gene therapy research

US life science researchers PerkinElmer has launched the Cellaca PLX Image Cytometry system. 

The first-of-its-kind benchtop platform enables researchers to assess multiple Critical  Quality Attributes (CQAs) of cell samples in a single automated workflow, including cell  identity, quality and quantity.  

The cutting-edge Cellaca PLX system, designed by the company’s Nexcelom unit, combines  best-in-class image cytometer hardware, software, validated consumables and trackable data  reporting all in one system without requiring complex calibration procedures or intense  training. To further streamline the customer experience, optimised reagent kits with validated  antibodies from PerkinElmer’s BioLegend business are also part of the proprietary solution.  

Pharmaceutical companies have invested heavily in cell and gene therapy, but they struggle  to assess the complex cell samples required to meet immense scientific demands and  regulatory rigor across their research and manufacturing processes

The new offering provides researchers with expanded cell sample CQA analysis options beyond  flow cytometry and staining methods, which historically have required a variety of different  instruments and analytical procedures. By combining these capabilities, researchers can now  detect multiple markers simultaneously (multiplexing) and perform immunophenotyping and  viability assays in seconds with an easy-to-use, modern user interface.  

"Pharmaceutical companies have invested heavily in cell and gene therapy, but they struggle  to assess the complex cell samples required to meet immense scientific demands and  regulatory rigor across their research and manufacturing processes," said Alan Fletcher, Senior  Vice President at PerkinElmer. "While the Cellaca PLX Image Cytometer platform  is therapeutic area agnostic, it is expected to be especially beneficial for researchers working  in CAR-T cell therapy who want to streamline their phenotyping of immune cells for  downstream processes."  

Sign up for your free email newsletter

PerkinElmer’s Nexcelom unit is a leading provider of automated cell counting technology and  image cytometry products for cell analysis, including the original and widely adopted Cellaca MX high-throughput automated cell counter.

Companies